The DOI matches its Crossref record.
Management of hypertensive disorders during pregnancy: summary of NICE guidance
Abstract
Salbutamol is used widely by elite athletes in treatment of asthma and related conditions, such as exercise-induced bronchoconstriction. In competitive sport, salbutamol is permitted by inhalation at doses up to 1600 µg/day, not to exceed 800 µg in any 12 hour period. WADA has established a urinary salbutamol Decision Limit for a presumed adverse analytical finding (AAF) of 1200 ng/mL. Urine salbutamol levels greater than this are deemed to be a result of prohibited use or excessive supratherapeutic inhalation. Studies have shown that under dehydrated conditions, exercise increases the risk of exceeding the Decision Limit after single inhaled doses of 1600 µg. One means of explaining an AAF is a Pharmacokinetic (PK) Study to establish whether an athlete is an outlier with higher urine concentrations than typical. However, a recent salbutamol case from the 2017 Vuelta a España, deemed it impractical and impossible to conduct a valid PK study capable of recreating the complex conditions of an athlete competing in such an event. Another means of explanation is the ‘Salbutamol Passport’. This is a statistical model derived from serial test data obtained from an event during periods of stable salbutamol use. After adjustment for dose and dosing frequency, the Salbutamol Passport can be used to predict an expected concentration range for days when an athlete might increase their salbutamol intake due to worsening symptoms. Since the number of tests during stable use is typically small, the method uses propagation of uncertainty in mean and variance of the log-transformed salbutamol concentrations to derive expected bands for any dose and frequency of interest. The method is demonstrated with data from a cyclist competing in the 2007 Giro d’Italia. The athlete provided four salbutamol tests whilst taking 400 ug/day with geometric mean 461 ng/mL (95% CL: 352–604) and one test of 1352 ng/mL after allegedly increasing his dose to 700 ug/day. Extrapolating the 400 ug/day data to 700 ug/day, and assuming an increase from twice-daily to three-times daily dosing, the Salbutamol Passport prediction is 1050 ng/mL (95%PI: 802–1375). Since the observed test falls within the 95% prediction interval, the result would not constitute an AAF. This conclusion is unchanged after adjustment of salbutamol levels to a urine specific gravity of 1.020.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Tranquilli, A. L., Dekker, G., Magee, L., Roberts, J., Sibai, B. M., Steyn, W., Zeeman, G. G., & Brown, M. A. (2014) · Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health · doi:10.1016/j.preghy.2014.02.001 · Cited by 1,417
Bushnell, C., McCullough, L. D., Awad, I. A., Chireau, M. V., Fedder, W. N., Furie, K. L., Howard, V. J., Lichtman, J. H., Lisabeth, L. D., Piña, I. L., et al. (2014) · Stroke · doi:10.1161/01.str.0000442009.06663.48 · Cited by 941
The two-stage placental model of preeclampsia: An update
Staff, A. C. (2019) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2019.07.004 · Cited by 598
Abalos, E., Cuesta, C., Carroli, G., Qureshi, Z., Widmer, M., Vogel, J., Souza, J., & on behalf of the WHO Multicountry Survey on Maternal and Newborn Health Research Network (2014) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.12629 · Cited by 528
Pregnancy-Induced hypertension
Kintiraki, E., Papakatsika, S., Kotronis, G., Goulis, D. G., & Kotsis, V. (2015) · Hormones · doi:10.14310/horm.2002.1582 · Cited by 330
Metadata
- Authors
- Visintin, C., Mugglestone, M. A., Almerie, M. Q., Nherera, L. M., James, D., Walkinshaw, S., & on behalf of the Guideline Development Group
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2010-08-25
- Volume
- 341
- Issue
- aug25 3
- Pages
- c2207-c2207
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- OpenAlex
- W2124500558
- Cited by
- 244
- References
- 0
- FWCI
- 9.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Management of hypertensive disorders during pregnancy: summary of NICE guidance. https://app.cochat.ai/papers/10.1136/bmj.c2207
- The paper
- Visintin, C., Mugglestone, M. A., Almerie, M. Q., Nherera, L. M., James, D., Walkinshaw, S., & on behalf of the Guideline Development Group. (2010). Management of hypertensive disorders during pregnancy: summary of NICE guidance. BMJ. https://doi.org/10.1136/bmj.c2207
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.